Skip to main content
. 2017 Sep 8;7:11009. doi: 10.1038/s41598-017-11188-y

Table 3.

SPM profiles in IL-1β stimulated diseased tendon stromal cells incubated in 15-epi-LXA4 and inhibitors of 15-PGDH.

DHA bioactive metabolome Q1 Q3 Tendon stromal cells Lipid mediators levels (pg/incubation)
Disease + IL-1β Disease + IL-1β + 15-epi-LXA4 Disease + IL-1β + Indo Disease + IL-1β + 15-epi-LXA4 + Indo Disease + IL-1β + SW033291 Disease + IL-1β + 15-epi-LXA4 + SW033291
RvD1 375 141 0.2 ± 0.2 1.0 ± 1.0
RvD2 375 141 0.6 ± 0.4 1.3 ± 0.3 0.1 ± 0.1
RvD3 375 147 0.3 ± 0.3 0.2 ± 0.1
RvD4 375 101 1.3 ± 1.3 1.9 ± 0.2
RvD5 359 199 34.0 ± 3.8 27.5 ± 5.2 1.3 ± 1.3** 0.3 ± 0.3** 8.6 ± 1.2** 2.1 ± 1.2**
RvD6 359 101 14.9 ± 2.5 20.4 ± 0.4* 4.1 ± 0.5** 4.1 ± 0.2** 3.1 ± 1.3** 1.0 ± 0.7**
17R-RvD1 375 141 1.2 ± 0.7 2.4 ± 1.3 0.3 ± 0.3
17R-RvD3 375 147 2.5 ± 1.5 4.5 ± 1.1 — *
PD1 359 153 7.0 ± 1.1 7.0 ± 1.0 1.5 ± 1.0* 0.8 ± 0.7** 1.4 ± 0.7** 0.7 ± 0.7**
17R-PD1 359 153 0.2 ± 0.1 0.3 ± 0.3 0.0 ± 0.0 0.1 ± 0.1 0.3 ± 0.2
10 S,17S-diHDHA 359 153 34.6 ± 5.2 64.3 ± 6.2* 0.6 ± 0.6* 1.8 ± 1.8** 0.9 ± 0.9** —**
MaR1 359 221 0.9 ± 0.9 13.2 ± 2.1** 0.0 ± 0.0 1.2 ± 1.2 0.7 ± 0.7
MaR2 359 191 0.5 ± 0.3 1.0 ± 0.1 0.7 ± 0.3 1.0 ± 0.6 2.1 ± 0.5*
7 S,14S-diHDHA 359 221 32.0 ± 5.2 22.1 ± 6.7 0.4 ± 0.4** —** —**
4 S,14S-diHDHA 359 101
14-oxo-MaR1 357 248 0.3 ± 0.2 0.4 ± 0.4 0.3 ± 0.2 0.1 ± 0.1 0.2 ± 0.2
n-3 DPA bioactive metabolome
RvD1n-3 DPA 377 143 3.2 ± 1.9 4.7 ± 0.6 0.1 ± 0.1 0.2 ± 0.2
RvD2n-3 DPA 377 261 0.4 ± 0.3 0.0 ± 0.0
RvD5n-3 DPA 361 263 25.4 ± 1.7 14.6 ± 2.4 * — ** 1.2 ± 1.2 — ** — **
PD1n-3 DPA 361 183 0.9 ± 0.5 2.2 ± 1.1 0.4 ± 0.4 0.8 ± 0.2 4.2 ± 1.8 0.9 ± 0.3
10 S,17S-diHDPA 361 183 16.8 ± 1.7 16.8 ± 2.3 5.2 ± 1.3 * 6.0 ± 0.7 ** 3.3 ± 0.5 ** 3.3 ± 1.0 **
MaR1n-3 DPA 361 249 3.9 ± 2.1 2.8 ± 0.6 0.4 ± 0.4 0.4 ± 0.2 0.1 ± 0.1
EPA bioactive metabolome
RvE1 349 195 0.0 ± 0.0 — ** 0.1 ± 0.1
RvE2 333 199 49.0 ± 11.7 44.3 ± 9.4 18.9 ± 2.0 * 22.3 ± 4.6 * 23.6 ± 4.0 * 24.6 ± 4.0
RvE3 333 201 0.4 ± 0.3 0.0 ± 0.0 0.0 ± 0.0
AA bioactive metabolome
LXA4 351 217 15.9 ± 10.6 4.9 ± 0.5** $ 2.4 ± 1.4
LXB4 351 221 1.4 ± 1.4 0.0 ± 0.0
5 S,15S-diHETE 335 235 121.8 ± 14.8 770.0 ± 168.4** — * 2.9 ± 2.9* — **
15epi-LXA4 351 217 253.2 ± 16.3** 291 ± 20.2**$$ 297.1 ± 23.9**##
15epi-LXB4 351 221 35.0 ± 7.3 45.5 ± 6.6 18.5 ± 3.6* 21.3 ± 5.9 — ** 5.4 ± 2.7*
15-oxo-LXA4 349 233 3.0 ± 0.5* 0.6 ± 0.1$$ 0.1 ± 0.0 0.5 ± 0.2* #
LTB4 335 195
5 S,12S-diHETE 335 195 45.6 ± 45.6 40.9 ± 31.1 0.0 ± 0.0
PGD2 351 189 50.0 ± 4.0 61.0 ± 9.4 0.7 ± 0.7** 30.8 ± 3.8* # 1.2 ± 1.2 ** 29.4 ± 6.0*#
PGE2 351 189 1655.4 ± 108.7 1275.0 ± 95.0 ** 4.6 ± 3.6** 4.8 ± 3.8** 154.5 ± 14.8** 74.6 ± 20.7** #
PGF 353 193 258.1 ± 26.0 258.8 ± 51.3 —** 0.0 ± 0.0** 2.4 ± 2.2** 5.7 ± 5.3**
TxB2 369 169 374.8 ± 31.5 367.9 ± 77.2 — ** 0.0 ± 0.0** 3.3 ± 3.0** 7.9 ± 7.4**

Tendon stromal cells (60,000 cells per well) were derived from diseased supraspinatus tendons. Cells were incubated for 24 h (37 °C) with indomethacin (indo; 10 µM), SW033291 (25 µM) or vehicle (2 h, 37 °C), then with 15-epi-LXA4 (10 nM) or vehicle (24 h 37 °C) and with IL-1β (37 °C; 24 h). Incubations were quenched using ice-cold methanol containing deuterium labelled internal standards and lipid mediators (LM) were identified and quantified using LM-profiling (see methods for details). Q1, M-H (parent ion) and Q3, diagnostic ion in the MS-MS (daughter ion). Results are expressed as pg/incubation. Mean ± SEM of n = 3 per incubation. *P < 0.05, **P < 0.01 vs Disease + IL1β incubations. $P < 0.05, $$P < 0.01 vs Disease + IL1β  + Indo; #P < 0.05, ##P < 0.01 vs Disease + IL1β  + SW. The detection limit was ~ 0.1 pg. -, Below levels found in media alone.